Gender Male
LinkedIn View on LinkedIn X (Twitter) View on X
Ryan Murray drives KiraGen Bio’s research strategy, pioneering next-generation CAR-T therapies for solid tumors. With a decade in cellular engineering at bluebird bio and Beam Therapeutics (BEAM-201), his expertise spans synthetic biology, tumor immunosuppression, and AI-driven gene editing. His PhD from Northeastern focused on overcoming
TME-mediated resistance in NSCLC, shaping KiraGen’s approach to tackling solid tumors.
